APR 20, 2019 08:41 PM PDT

Underwater Forest May Bring New Therapeutics

WRITTEN BY: Nouran Amin

Microbes that produce defensive compounds have contributed to the major source of antibiotics and other therapeutics. However, due to the rise of antibiotic-resistant bacteria, researchers are now seeking new drug candidates offshore.

Currently, a family of sea-dwelling bacteria known as Actinobacteria have helped in producing new antibiotics with their rich source of bioactive microbial compounds. Now a study published in Frontiers in Microbiology, revealed that an underwater species of seaweed, called Laminaria ochroleuca, serves as a rich source of bacteria with antimicrobial and anticancer compounds--the discovery can lead to new therapeutics.

"About half of the 20,000+ microbe-derived drug candidates currently known come from Actinobacteria," says senior study author Dr. Maria de Fátima Carvalho of the Interdisciplinary Center of Marine and Environmental Research (CIIMAR), Portugal. "Now the supply of new species on land -- where they form spores and branched networks just like a fungus -- is beginning to run out. Several novel drug leads derived from marine Actinobacteria are already known. These include anticancer agent salinosporamide A, currently in clinical trials, and several new antibiotics that are effective against drug-resistant infections like MRSA and tuberculosis."

The study showed that extracts of the seaweed L. ochroleuca is a rich source of Actinobacteria with promising antimicrobial and anticancer activities.

"The brown alga Laminaria ochroleuca forms complex structures called kelp forests, which are among the most diverse and productive ecosystems in the world," says Carvalho. "But until now, no-one had characterized the Actinobacteria that live inside L. ochroleuca. Seven of the extracts inhibited growth of breast and particularly nerve cell cancers, while having no effect on non-cancer cells."

Kelp forests are among the most diverse and productive ecosystems in the world. Image: Shutterstock.

"We identified extracts from two Actinobacteria strains that do not match any known compounds in the most comprehensive international database of natural bioactive compounds. We intend to follow up on these exciting results."

Source: Frontiers

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JAN 16, 2019
Genetics & Genomics
JAN 16, 2019
Gene Therapy for a Leading Cause of Infant Death is Closer to Market
New treatments for some diseases can have extremely high price tags. One example is Zolgensma, which might cost $5 million per patient....
FEB 11, 2019
Chemistry & Physics
FEB 11, 2019
Actinium-based Targeted Alpha Therapy Delivers A Combo Punch
Radiotherapy is a staple among many medical interventions to treat cancer. Besides external beam radiotherapy and sealed radio-source therapy, it is common...
FEB 17, 2019
Drug Discovery
FEB 17, 2019
Drug Combination May Become Standard Treatment for Metastatic Kidney Cancer
Reporting from results of a phase 3 clinical trial, patients with metastatic kidney cancer may soon receive a new standard treatment involving a combinatio...
MAR 10, 2019
Microbiology
MAR 10, 2019
Bacteria on Frog Skin Can Help Fight Fungal Infections
In recent years, fungal disease has decimated amphibian populations; some species went extinct. But others withstood the epidemic....
APR 30, 2019
Health & Medicine
APR 30, 2019
Pain is biologically different for women and men: drugs could be too
Women and men have biologically different pathways for chronic pain. Research published in the journal Brain revealed that different genes and pain si...
APR 24, 2019
Drug Discovery
APR 24, 2019
Self-Inflating Capsule To Tackle Obesity
A team of collaborative researchers have developed a self-inflating weight management capsule used for the treatment of obesity called the EndoPil. The &ls...
Loading Comments...